Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new articles that discuss program directors’ response to the use of generative AI for personal statements, the good news for neurology based on the 2024 Match Day, and the AHS statement on CGRP-targeting therapies as a game changer for migraine treatment.

Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.

Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic events.

Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the impact of SARS-CoV2 on dopamine neurons, a European Medicines Agency warning about valproate risks for men, and neurologists on the pros and cons of working locum tenens.

Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the use of AI in EMS systems for stroke detection, the association between human growth hormone and iatrogenic Alzheimer’s, and seizure dogs for refractory epilepsy.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a new study showing retinal vascular perfusion as a migraine biomarker, clinical and pathophysiological correlates of posterior cortical atrophy, and advances in gene therapies for neuromuscular disorders.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing the cerebral amyloid angiopathy as a risk factor for nontraumatic subdural hemorrhage, AI beats humans in neurology-like boards, and the impact of popular weight loss drugs on neurologic conditions.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies on the impact of deep brain stimulation on cognition in severe traumatic brain injury and how adaptive functioning is impacted in children exposed to antiseizure drugs in utero, and the editorial board’s picks for the best advances of 2023.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing double the suicide risk among Parkinson’s patients; underrepresentation of non-White people in Alzheimer’s trial related to biomarker eligibility; early immune systems changes may play early role in ALS and Parkinson's.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing serotonin depletion associated with long COVID; implantable cardiac monitors detect Afib 3 years post-stroke; and what Medicare’s decision to cover PET amyloid scans means for neurologists.